Bellack focuses on licensing, collaborations, and other strategic and commercial transactions for clients engaged in all aspects of the life sciences and healthcare industries. He represents a wide range of clients from startups and early-stage pharmaceutical and biotech companies to global pharmaceutical and medical device companies. Bellack has also represented founders, venture funds, universities, and technology companies entering the life sciences and healthcare space. Before joining Goodwin, Bellack practiced at another international law firm, where he served as Americas co-head of the firm’s life sciences transactions team.
“Having licensing lawyers of Adam’s caliber on board is invaluable to the growing number of our clients with therapeutics approaching commercialization, and reinforces our practice as the global destination for the life sciences industry,” said Mitchell Bloom, chair of Goodwin’s Life Sciences practice. “His experience representing biotech, pharmaceutical, and medical technology companies and investors throughout all stages of the life cycle adds significant depth to our practice as Goodwin continues to partner with clients at the intersection of capital and innovation.”
Bellack, who can be reached at email@example.com and 202.346.4097, joins Goodwin as the firm continues to build its life sciences platform that serves clients globally. Within the past three months, the firm welcomed Healthcare partners Delphine O’Rourke and Brian Bewley in New York and Washington, D.C., respectively, and Life Sciences Intellectual Property partner Sabrina Poulos in San Francisco.
Last month, Reuters reported that Goodwin “has advised on deal after deal in 2020, blowing past perennial top leaders for M&A volume as its key client sectors — life sciences and technology — stood out as engines of the pandemic-era economy.”
According to statistics compiled by Endpoints News, Goodwin has represented more clients in issuer-side biotech IPOs than any other law firm from January 1, 2020, through September 1, 2020.
Mergermarket’s Deal Drivers Americas HY Report has named Goodwin the number one firm (by deal count) for technology, healthcare, and life sciences M&A in North America during H1 2020, and Pitchbook’s Global League Tables have named Goodwin the only law firm in Q2 2020 to finish in the top five (by deal count) for global venture capital, M&A, and private equity-healthcare transactions.
Goodwin’s Life Sciences practice represents leading public and private life sciences companies and investors across their entire life cycles — including financings, capital market transactions, M&A, collaborations and licensing, intellectual property, and regulatory matters.